{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:12:24Z","timestamp":1783062744162,"version":"3.54.6"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pituitary metastases are rare, accounting for only 1% of all pituitary tumor resections. Prostate adenocarcinoma, a common malignancy in men, seldom metastasizes to the pituitary gland, with only a few reported cases. Given their rarity and non-specific clinical presentation, pituitary metastases are often mistaken for primary sellar lesions. Advanced imaging techniques, including Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET)\/Computed Tomography (CT) and molecular diagnostics, such as DNA methylation profiling, can aid in accurate diagnosis and differentiation from pituitary adenomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report the case of a 71-year-old male with a history of prostate adenocarcinoma who presented with biochemical recurrence and underwent PSMA PET\/CT imaging, revealing intense tracer uptake in the pituitary gland. Magnetic Resonance Imaging (MRI) findings were suggestive of a pituitary macroadenoma, and the patient developed bitemporal hemianopia, necessitating transsphenoidal surgical resection. Histopathological and immunohistochemical analyses were not compatible with a primary pituitary lesion, prompting further investigation via DNA methylation profiling. The analysis revealed a DNA-methylation signature consistent with prostate carcinoma, confirming pituitary metastasis. The patient subsequently received systemic treatment with androgen deprivation therapy, abiraterone, and docetaxel, achieving an excellent biochemical and imaging response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the importance of considering metastatic prostate cancer in the differential diagnosis of pituitary lesions, particularly when PSMA PET\/CT shows focal uptake in atypical locations. Integration of histopathological, immunohistochemical, and molecular techniques, such as DNA-methylation profiling, was essential for confirming the diagnosis. Clinicians should remain vigilant for atypical metastatic presentations and leverage advanced diagnostic tools to ensure accurate diagnosis and optimal patient management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1618256","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:46:20Z","timestamp":1750225580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Pituitary metastasis from prostate adenocarcinoma: an integrated diagnosis via 68Ga-PSMA PET\/CT and methylome analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"N.","family":"Bianchetto Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. C.","family":"Mainta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fitsiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Colarusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tsantoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Egervari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3171\/foc.2004.16.4.9","article-title":"Metastases to the pituitary gland","volume":"16","author":"Fassett","year":"2004","journal-title":"Neurosurg Focus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11102-018-0899-x","article-title":"Twelve cases of pituitary metastasis: a case series and review of the literature","volume":"21","author":"Castle-Kirszbaum","year":"2018","journal-title":"Pituitary"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1530\/EC-18-0338","article-title":"Pituitary metastasis: a rare condition","volume":"7","author":"Javanbakht","year":"2018","journal-title":"Endocr Connect"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11604-023-01400-7","article-title":"Imaging of pituitary tumors: an update with the 5th WHO classifcations\u2014part 1. Pituitary neuroendocrine tumor (pit NET)\/pituitary adenoma","volume":"41","author":"Tsukamoto","year":"2023","journal-title":"Jpn J Radiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-024-01759-2","article-title":"Epi DiP\/Nano DiP: a versatile unsupervised machine learning edge computing platform for epigenomic tumour diagnostics","volume":"12","author":"Hench","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3174\/ajnr.A8302","article-title":"Distinguishing pituitary metastasis and pituitary neuroendocrine tumors through conventional MR imaging and clinical features","volume":"45","author":"Yuzkan","year":"2024","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4274\/mirt.galenos.2021.97752","article-title":"Mild 68Ga PSMA-11 uptake in incidental pituitary adenoma","volume":"31","author":"Beyhan","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-023-04355-x","article-title":"Identification of incidental brain tumors in prostate cancer patients via PSMA PET\/CT","volume":"163","author":"McLaughlin","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41467-020-20603-4","article-title":"Sarcoma classification by DNA methylation profiling","volume":"12","author":"Koelsche","year":"2021","journal-title":"Nat Commun"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13148-022-01365-w","article-title":"Sarcoma classification by DNA methylation profiling in clinical everyday life: the Charit\u00e9 experience","volume":"14","author":"Roohani","year":"2022","journal-title":"Clin Epigenetics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cjp2.215","article-title":"DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the \u2018DKFZ sarcoma classifier\u2019","volume":"7","author":"Lyskjaer","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref16","unstructured":"2025"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41698-024-00705-8","article-title":"Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression","volume":"8","author":"Diossy","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1123362","DOI":"10.3389\/fonc.2023.1123362","article-title":"CHD1, a multifaceted epigenetic remodeler in prostate cancer","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1618256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:46:22Z","timestamp":1750225582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1618256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":18,"alternative-id":["10.3389\/fmed.2025.1618256"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1618256","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1618256"}}